Retreatment with Pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of peylated interferon-based therapy

Canadian Journal of Gastroenterology

Volumn 23, Issue 3, 2009, Pages 180-184

  Yoshida, Eric M ^a   Sherman, Morris ^b   Bain, Vincent G ^c   Cooper, Curtis L ^d   Deschênes, Marc ^e   Marotta, Paul J ^f   Lee, Samuel S ^g   Krajden, Mel ^h   Witt Sullivan, Helga ⁱ   Bailey, Robert J ^j   Usaty, Christopher ^k   Peltekian, Kevork ^l  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j ROYAL ALEXANDRA HOSPITAL   (Canada)

^k Roche   (Canada)

^l DALHOUSIE UNIVERSITY   (Canada)

more..

Author keywords

Failure; Hepatitis C; Nonresponse; Peginterferon; Relapse; Ribavirin; Treatment

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; DOSE RESPONSE; DRUG COMBINATION; LIVER CIRRHOSIS; MIDDLE AGED; PATHOPHYSIOLOGY; RECURRENT DISEASE; RETREATMENT; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65549091525     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/470532     Document Type: Article

References (14)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
2. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006:130:231-64.
3. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: Consensus guidelines. Can J Gastroenterol 2007;21 (Suppl C):25C-34C.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 200l;358:958-65.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic heparitis C virus infection. N Engl J Med 2002;347:975-82.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomised study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
7. Sherman M, Yoshida EM, Deschenes M, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006;55;1631-38.
8. Bedosa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C: The METAVIR Co-operative Study Group. Hepatology 1996;24:289-93.
9. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-99.
10. Krawitt EL, Ashikaga T, Gordon SR, et al. Peginteferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005;43:243-49.
11. Berg C, Goncales FL Jr, Bernstein DE, et al. Re-treatment of chronic hepatitis C patients after relapse: Efficacy of peginterferon-alpha-2a (40 kDa) amd ribavirin. J Viral Hepat 2006;13:435-40.
12. Poynard T, Schiff E, Terg R, et al. Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon/ribavirin (I/R) nonresponders (NR): Final results from the EPIC3 program [abstract 988]. J Hepatol 2008;48(Suppl 2):S369.
13. Jensen DM, Freilich B, Andreone P, et al. Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: Final efficacy and safety outcomes of the REPEAT study [abstract LB4]. Hepatology 2007;46 (Suppl 1):291-2A.
14. Marcellin P, Freilich B, Andreoni P, et al, HCV-RNA status at week 12 of treatment with peginterferon alfa-2a/RBV predicts SVR in patients with prior non-response to pegylated interferon alfa-2b/RBV: Results from REPEAT study [abstract 805]. J Hepatol 2008;48 (Suppl 1) S301.